Hamza Suria - 10 Feb 2022 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Reporting relationship: President, CEO, Director
Issuer ticker: ANAB
Reported as of: 10 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Feb 2022, 15:49:27 UTC
Prior SEC filing: 22 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Eric Loumeau, Attorney-in-Fact

Key filing fact

Hamza Suria filed Form 4 for ANAPTYSBIO, INC (ANAB) on 14 Feb 2022.

Key facts

This page summarizes Hamza Suria's Form 4 filing for ANAPTYSBIO, INC (ANAB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Feb 2022, 15:49.

Change

Previous filing in this sequence was filed on 22 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANAB transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +200,000
Change %
Price: $0.000000
Shares after: 200,000
Date: 10 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $30.44
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Footnote F2

In addition to the remaining options to purchase 200,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,118,893 shares of common stock, which options vest according to their terms, and (ii) 68,600 shares of common stock held directly.